Dalteparin as a Novel Therapeutic Agent to Prevent Diabetic Encephalopathy by Targeting Oxidative Stress and Inflammation.

Zeinivand, Motahareh; Nahavandi, Arezo; Baluchnejadmojarad, Tourandokht; Roghani, Mehrdad; Golab, Fereshteh

Zeinivand, Motahareh; Nahavandi, Arezo; Baluchnejadmojarad, Tourandokht; Roghani, Mehrdad; Golab, Fereshteh.

Afiliación

Zeinivand M; Department of Physiology, School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Nahavandi A; Department of Physiology, School of Medicine, Iran University of Medical Sciences, Iran, Iran.
Baluchnejadmojarad T; Department of Physiology, School of Medicine, Iran University of Medical Sciences, Iran, Iran.
Roghani M; Department of Physiology, School of Medicine, Shahed University, Tehran, Iran.
Golab F; Cellular and Molecular Research Center, Iran University of Medical Sciences, Tehran, Iran.

Basic Clin Neurosci ; 11(6): 795-804, 2020.

Article en En | MEDLINE | ID: mdl-33850616

Palabras clave

Diabetic encephalopathy; Hepcidin; Iron; Type1 diabetes

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Basic Clin Neurosci Año: 2020 Tipo del documento: Article País de afiliación: Irán Pais de publicación: Irán

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google